Horizon Therapeutics

Horizon Therapeutics

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD201520162017201820192020
Revenues--145m169m204m216m
% growth---17 %21 %6 %
Profit--33.0m53.0m67.0m72.0m
% profit margin--23 %31 %33 %33 %
R&D budget41.8m63.8m68.2m79.2m101m-
R&D % of revenue--47 %47 %50 %-

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

$6.0m

Series A

$15.0m

Series B

$30.0m

Series C
N/A

$12.0m

Debt
N/A

N/A

IPO
*
N/A

$50.8m

Post IPO Equity
*
N/A

$81.0m

Post IPO Equity
N/A

$150m

Post IPO Debt
N/A

$300m

Post IPO Debt
*
N/A

$141m

POST IPO SECONDARY
*
N/A

$862m

Post IPO Debt
*
N/A

$300m

Post IPO Debt
*
N/A

$345m

Post IPO Equity
*
N/A

$600m

Post IPO Debt
*
N/A

$963m

Post IPO Equity
*

$28.3b

Valuation: $28.3b

Acquisition
Total Funding€46.4m

Recent News about Horizon Therapeutics

Edit
More about Horizon Therapeuticsinfo icon
Edit

Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines that address critical needs for people affected by rare and rheumatic diseases. The company operates primarily in the healthcare and pharmaceutical markets, serving patients, healthcare professionals, and medical institutions globally. Horizon Therapeutics generates revenue through the sale of its proprietary medications, which are often developed through extensive research and clinical trials. The company has a robust portfolio of approved medicines and a pipeline of potential therapies aimed at treating conditions with significant unmet medical needs. Horizon Therapeutics' business model is centered around the discovery and commercialization of specialty medicines, leveraging its expertise in drug development and patient-centric approach to drive growth and improve patient outcomes. The company also collaborates with academic institutions and other organizations to advance its research and development efforts.

Keywords: biopharmaceuticals, rare diseases, rheumatic diseases, innovative medicines, patient outcomes, healthcare, pharmaceutical, clinical trials, specialty medicines, drug development.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
  • Edit
Raptor Pharmaceuticals
ACQUISITION by Horizon Therapeutics Sep 2016
Vidara Therapeutics
ACQUISITION by Horizon Therapeutics Mar 2014
Crealta Pharmaceuticals
ACQUISITION by Horizon Therapeutics Jan 2016
River Vision
ACQUISITION by Horizon Therapeutics May 2017
Hyperion Therapeutics
ACQUISITION by Horizon Therapeutics Mar 2015
Viela Bio
ACQUISITION by Horizon Therapeutics Mar 2021
Nitec Pharma AG
ACQUISITION by Horizon Therapeutics Apr 2010
Curzion Pharmaceuticals
ACQUISITION by Horizon Therapeutics Apr 2020